<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1630">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02091700</url>
  </required_header>
  <id_info>
    <org_study_id>OPT1010</org_study_id>
    <nct_id>NCT02091700</nct_id>
  </id_info>
  <brief_title>ObseRvation of PeripHEral rEtinal Morphology in Normals</brief_title>
  <acronym>ORPHEE</acronym>
  <official_title>ObseRvation of PeripHEral rEtinal Morphology in Normals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optos, PLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Optos, PLC.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To develop a database of the peripheral retinal circulation using ultra widefield
      fluorescein angiography (UWF-FA) imaging for the Optos COE platform.  This database will
      serve as a quantitative reference tool for the comparison of subjects to a database of known
      normal subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Develop a database of  peripheral retinal circulation in normals using UWF-FA imaging</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Develop a database of peripheral retinal morphology on age stratified normals using color, AF and FA imaging</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Normals</arm_group_label>
    <description>Subjects with normal visual and retinal function will be enrolled</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fluorescein angiography</intervention_name>
    <arm_group_label>Normals</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Normal subjects with no known retinal disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects older than 20 years old with good general health.

          -  Subject is capable of giving consent.

          -  The subject is able and willing to comply with the study procedures.

          -  Women with childbearing potential may be included.

          -  Subjects with ocular media clear enough to allow good quality ocular imaging.

          -  Normal subjects with no known retinal disease.

        Exclusion Criteria:

          -  Subjects under 20 years old or over 80 years old.

          -  Subjects with contraindications to dilation

          -  Subjects with a history of epilepsy.

          -  Subjects who are or who may be pregnant.

          -  Subjects with past history of any vitreoretinal disease or surgery such as retinal
             detachment, epiretinal membrane, or vitreous hemorrhage.

          -  Subjects with any ocular condition that interferes with good quality image
             acquisition, such as corneal opacities, cataract, and dense vitreous hemorrhage.

          -  Subjects with any evidence of any retinal or optic nerve disease including glaucoma.

          -  Subjects with any anterior segment disease with the exception of common ocular
             surface disorders (blepharitis, dry eye).

          -  Subjects with medical conditions that interfere with the subject's compliance to
             study procedures such as inability of the subject to maintain steady head or eye
             positioning as in patients of ataxia or nystagmus.

          -  Subjects with a history of Diabetes, High Blood Pressure, Vascular disease
             (cardiovascular, peripheral vascular or cerebrovascular)

          -  Subjects on vasodilators.

          -  Subject's refusal.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Singer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Center Ophthalmology Associates</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cathy Ellis, BS, MT</last_name>
    <phone>210-697-2036</phone>
    <phone_ext>2270</phone_ext>
    <email>cathy@mcoaeyecare.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Center Ophthalmology Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Ellis, BS, MT</last_name>
      <phone>210-697-2036</phone>
      <phone_ext>2270</phone_ext>
      <email>cathy@mcoaeyecare.com</email>
    </contact>
    <contact_backup>
      <last_name>Tamara Urias</last_name>
      <phone>201-697-2036</phone>
      <phone_ext>2239</phone_ext>
      <email>turias@mcoaeyecare.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Singer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Darren J Bell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 18, 2014</lastchanged_date>
  <firstreceived_date>March 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Normal</keyword>
  <keyword>Healthy</keyword>
  <keyword>Normal healthy patient</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
